Herpes Simplex Virus 2 News and Research

RSS

Herpes Simplex Virus-2 is a sexually transmitted viral infection, which often produces painful sores, usually in the genital area. Once infected, an individual may carry the virus and be subject to recurrent bouts of infection. Some estimate that as many as 20 percent of the adult population in the United States has been exposed to the virus.

Female sex hormone estradiol may protect women against sexually transmitted viral infections

A team of researchers led by McMaster University's Charu Kaushic has revealed for the first time how estradiol, a female sex hormone present during the menstrual cycle and found in oral contraceptives, may work to protect women against sexually transmitted viral infections.

6 May 2016

LJI study could provide important target for autoimmune disease interventions

Follicular helper T cells (Tfh cells), a rare type of T cells, are indispensable for the maturation of antibody-producing B cells. They promote the proliferation of B cells that produce highly selective antibodies against invading pathogens while weeding out those that generate potentially harmful ones.

3 May 2016

ZOTEN nanoparticles can help develop natural immunity against genital herpes

An effective vaccine against the virus that causes genital herpes has evaded researchers for decades. But now, researchers from the University of Illinois at Chicago working with scientists from Germany have shown that zinc-oxide nanoparticles shaped like jacks can prevent the virus from entering cells, and help natural immunity to develop.

28 Apr 2016

Hormonal contraception may increase susceptibility of women to genital infection

Women account for approximately half of all individuals living with HIV worldwide, and researchers wanted to identify the risk factors that increase susceptibility of women to genital infection.

20 Apr 2016

Scientists reveal mechanism involved in regulation of lymphangiogenesis

After an injury to tissues, such as in organ transplantation, the body grows new lymphatic vessels in a process known as lymphangiogenesis. A new study in Nature Communications reveals a mechanism involved in the regulation of this process, specifically in corneal transplants and infectious eye disease.

13 Apr 2016

Forensic scientists find that HSV-1 strains could be useful for tracing a person's history

The genomes of two distinct strains of the virus that causes the common lip cold sore, herpes simplex virus type 1 (HSV-1), have been identified within the same person -- an achievement that could be useful to forensic scientists for tracing a person's history.

6 Apr 2016

Researchers reveal how stress conditions favor lytic reactivation of herpesviruses

Hiding their DNA genome inside the nucleus of the infected cells, the herpesviruses establish a lifelong infection in humans. Not well defined stress conditions are known to wake up these parasites from their dormancy - the latent phase - and reactivate the production of new viral progeny, eventually causing cell death by lysis - the lytic phase.

25 Feb 2016

High school wrestlers have highest number of skin infections

The first national survey of skin infections among high school athletes has found that wrestlers have the highest number of infections, with football players coming in a distant second, according to researchers at the University of Colorado Anschutz Medical Campus.

4 Feb 2016

Study shows several Envigo rat models susceptible to genital HSV-2 infection

A scientific collaboration between Envigo and the Department of Infectious Disease at the University of Gothenburg, Sweden has unveiled study findings into rat models and their susceptibility to intra-vaginal herpes simplex virus-2 (HSV-2) infection.

2 Feb 2016

Rutgers Cancer Institute scientist leads phase III trial of FDA-approved viral melanoma therapy

The U.S. Food and Drug Administration has approved a viral melanoma therapy that was the focus of a phase III clinical trial led by Rutgers Cancer Institute of New Jersey Associate Director for Clinical Science and Chief Surgical Officer Howard L. Kaufman, MD, FACS.

29 Oct 2015

Over 3.7 billion people under 50 have genital HSV-1 infection, shows WHO report

More than 3.7 billion people under the age of 50 – or 67% of the population – are infected with herpes simplex virus type 1 (HSV-1), according to the World Health Organization’s first global estimates of HSV-1 infection published today in the journal PLOS ONE.

29 Oct 2015

FDA permits marketing of first CSF nucleic acid-based test for detection of multiple pathogens

The U.S. Food and Drug Administration today allowed marketing of the first cerebrospinal fluid (CSF) nucleic acid-based test for simultaneous detection of multiple pathogens that can cause central nervous system infections.

12 Oct 2015

Quest Diagnostics receives FDA 510(k) clearance for Simplexa HSV 1 & 2 Direct molecular test

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that its Focus Diagnostics products business has received FDA 510(k) clearance to add the genital swab claim to its Simplexa HSV 1 & 2 Direct molecular test on the Integrated Cycler.

From Quest Diagnostics 4 Sep 2015

Blavatnik Biomedical Accelerator funds advanced biomedical research projects

A few years ago, Andrew Myers' laboratory discovered a new way to synthesize an important class of antibiotics that could one day tackle the toughest, most resistant infections.

20 Aug 2015

Researchers capture images of immune cell interactions rallying to destroy herpes simplex virus

Doctor Scott Mueller and colleagues from the University of Melbourne's Department of Microbiology and Immunology at the Doherty Institute used state-of-the-art microscopy to painstakingly capture images of the interactions of three crucial types of immune cells rallying to destroy herpes simplex virus.

19 Aug 2015

Reducing amyloid fibril levels in semen may help reduce transmission of HIV

There may be two new ways to fight AIDS -- using a heat shock protein or a small molecule - to attack fibrils in semen associated with the human immunodeficiency virus (HIV) during the initial phases of infection, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

18 Aug 2015

NanoViricides speeds up HerpeCide drug development program

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reports that it is accelerating its HerpeCide drug development program.

17 Aug 2015

Anna Nele Meckler and Armelle Corpet to receive SNSF's 2015 Marie Heim-Vögtlin Prize

The biologist Armelle Corpet and paleo-climatologist Anna Nele Meckler will receive the 2015 Marie Heim-Vögtlin (MHV) Prize. This distinction rewards their remarkable scientific work supported by a MHV grant. The prize will be bestowed on 23 September 2015 at the Swiss National Science Foundation.

4 Jun 2015

Roche announces FDA 510(k) clearance for cobas HSV 1 and 2 Test

Roche announced today that the US Food and Drug Administration has provided 510(k) clearance for the cobas HSV 1 and 2 Test for the direct detection and differentiation of HSV-1 and HSV-2 DNA in anogenital specimens from symptomatic patients. With dual target detection and automation, the cobas HSV 1 and 2 Test provides laboratories with the capability to report up to 94 results in significantly less time than traditional methods and provides a simplified workflow for sample handling in the laboratory.